"Our research confirmed that inhibiting c-Abl activity had a direct effect on a-synuclein aggregation and disease progression. We believe c-Abl is a promising target for pharmacological intervention, but we need to develop a neurotherapeutic that can penetrate the blood-brain barrier and has the proper pharmacokinetics."
Seulki Lee, CEO of Neuraly Inc. and assistant professor at Johns Hopkins School of Medicine, on the firm's collaboration with 1st Biotherapeutics Inc. to co-develop brain-penetrant c-Abl inhibitors for Parkinson's disease

"To the best of our knowledge, we are the first to show that the mechanism underlying anti-VEGF resistance lies not within the tumor tissue, but rather other healthy organs, i.e. kidney-derived EPO. This is a surprising and new concept, which may lead to a paradigm shift for future anti-angiogenic therapy."
Yihai Cao, professor of vascular biology in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institutet in Stockholm and study leader in gain-of-function studies, which demonstrated EPO protected tumor vessels from anti-VEGF treatment and impaired its antitumor effects

"This idea of immunoediting or the immune system shaping the cancer and the cancer changing genetically to escape from the immune system attack, I think it's something that is becoming more and more important."
Antoni Ribas, of the University of California Los Angeles Medical Center, and a co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

"From cancer drugs to expensive eye drops, many drug companies insist on selling their products in excessively large, one-size-fits-all vials that contain more medicine than the average patient needs. This is a colossal and completely preventable waste of taxpayer dollars, and it means American patients and hard-working families are paying for medication that gets tossed in the trash. Instead of allowing the pharmaceutical industry to profit at our expense, it's time we put an end to this wasteful spending."
Sen. Dick Durbin (D-Ill.), who is co-sponsoring a proposed Reducing Drug Waste Act